Ron Paul Gallemore | |
|---|---|
| Born | December 18, 1964 |
| Education | University of California, Irvine University of California, San Francisco |
| Years active | 1992–Present |
| Known for | Research in the treatment of macular degeneration |
| Medical career | |
| Profession | Surgeon |
| Institutions | Retina Macula Institute Jules Stein Eye Institute |
| Sub-specialties | Diseases of the Retina Macular Degeneration |
| Research | Neuroscience Macular Degeneration |
Ron P. Gallemore is a registered ophthalmologist with the American Academy of Ophthalmology[1] involved in research and treatment of diseases of the macula and retina.
Gallemore attained his undergraduate degree from the University of California, Irvine, before going on to complete his M.D. at the School of Medicine at the University of California, San Francisco. He completed his Ph.D. in the field of neuroscience and began a career focusing on the physiology and biophysics of retinal function.
In his progression of training he conducted his internship at the Mercy Hospital and Medical Center in San Diego, before going on to undertake his residency at the Jules Stein Eye Institute at the UCLA Medical Center, Los Angeles, where he later became a clinical instructor. He completed his vitreoretinal surgery fellowship at Duke University under Dr. Robert Machemer, known as the founder of modern vitreoretinal surgery.[2]
Gallemore has been the recipient of numerous awards, including the Heed and Knapp Fellowship award, the Dr. Charles Schepens Award, the Dr. Ron Michels Award,[3] and the Jules Stein Eye Institute Alumni Research Award.
He continues to make contributions in the field of diseases of the retina through research, clinical trials, clinical instruction, and public lectures and appearances. In 2007 he founded the Retina Macula Institute where he is currently the principal doctor and surgeon.
Gallemore has published 60 peer-reviewed articles listed in Web of Science. His most cited has been the phase II multi-center study, "Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration – 2-year results of a randomized clinical trial." by Greve, MDJ; Hinz, BJ; Schulha, M, et al. Archives of Ophthalmology 123 (4): 448–457 (2005), Cited 70 times as of June 2009.
Other highly cited papers include: